42 results about "Conjunctivitides" patented technology

The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium animalis for relieving eye allergy and application of the bifidobacterium animalis. The invention provides an application of bifidobacterium animalis subsp. Lactis in preparation of a product for relieving eye allergy, the bifidobacterium animalis subsp. Lactis is Def +, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.35798. The Bifidobacterium animalis subsp. Lactis Def < + > provided by the invention can relieve the eye itching symptom, relieve red and swollen eyelids, reduce conjunctiva and cornea injury, relieve eye discomfort, relieve globular conjunctivitis cell infiltration, improve corneal epithelium thickening lesion, improve the anti-inflammatory ability and improve allergic conjunctivitis, keratitis and blepharitis marginata in a targeted manner. The eye drops are high in safety and resistant to gastrointestinal fluid, and a safe and long-acting scheme is provided for eye allergic diseases.

The invention relates to compound herba houttuyniae eye drops as well as a preparation method and application of the compound herba houttuyniae eye drops. Comprising the following preparation raw materials in percentage by mass: 1-6% of a herba houttuyniae extracting solution, 1-5% of an aglaia odorata extracting solution, 1-2% of a gelidium amansii extracting solution, 0.1-0.3% of acyclovir, 0.1-0.3% of tobramycin, 0.01-0.1% of dexamethasone sodium phosphate, 0.1-1% of sodium hyaluronate, 0.1-3% of glycerol and 88-93% of purified water. According to the compound herba houttuyniae eye drops prepared by the preparation method disclosed by the invention, the herba houttuyniae extracting solution, the aglaia odorata extracting solution, the gelidium amansii extracting solution, the acyclovir, the tobramycin and the dexamethasone sodium phosphate are combined for use, so that the compound herba houttuyniae eye drops have a relatively good curative effect on pets suffering from bacterium and virus mixed infection type conjunctivitis / keratitis; the compound herba houttuyniae eye drops are good in high-temperature-resistant storage stability and good in curative effect, the problem of frequent administration can be reduced, and the compound herba houttuyniae eye drops are more convenient to use and store.

The present invention relates to a single dose plastic container comprising between 0.2 and 3.0 ml of an aqueous pharmaceutical composition comprising from 0.50 to 1.20 % by weight of povidone-iodine and to its use in the treatment of conjunctivitis.

The present invention relates to an ophthalmic composition in the form of an aqueous solution containing levofloxacin or salt or derivative thereof and ketorolac or salt or derivative. The present invention relates to an ophthalmic composition in the form of an aqueous solution containing levofloxacin or salt or derivative thereof and ketorolac or salt or derivative thereof, for use in a method for the treatment of conjunctivitis and for the prevention or treatment of inflammation or prevention of infection after cataract surgery in a subject, according to a dosage regimen that improves patient compliance and tolerability and enables the prevention and treatment of intermediate / antibiotic-resistant infections.

The present invention provides a novel multi-strain probiotic formulation and relates to the use of the multi-strain formulation in therapy, in particular for the treatment or prevention of immunological or allergic diseases / disorders, such as allergic rhinitis or allergic conjunctivitis. In addition, the present invention also provides a novel therapeutic regimen that is easy to follow using the probiotic formulations provided herein.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

The invention discloses a preparation method of a non-Newtonian fluid-based temperature-shear dual response type ophthalmic sustained-release drug carrier, and belongs to the technical field of ophthalmic medicines. The preparation is composed of a dispersed phase (a temperature response type targeting nano-drug carrier) and a continuous phase (a non-Newtonian fluid matrix), wherein the mass fraction of the dispersed phase in the continuous phase is 0.5-2%. The temperature response type targeted nano-drug carrier is of a core-shell two-layer structure, the core is composed of a PLGA-PEG copolymer and an active drug, the shell is formed by grafting poly N-isopropylacrylamide (PNIPAM) and hyaluronic acid, and the lowest critical solution temperature (LCST) of the PNIPAM is 35-37 DEG C; the non-Newtonian fluid matrix is a pseudoplastic fluid, is composed of Carbomer 940 and triethanolamine, and has a shear thinning characteristic. The preparation method comprises the following three steps: preparation of the temperature response type targeting nano-drug carrier, preparation of the non-Newtonian fluid matrix and low-speed dispersion and compounding of the two. According to the invention, shear-response convenient administration, temperature-response precise drug release and long-acting retention synergism are realized, the bioavailability of the drug and the compliance of a patient are remarkably improved, the stability is excellent, the preparation process is simple and controllable, and the preparation method is suitable for long-acting targeted therapy of chronic eye diseases such as allergic conjunctivitis, chronic xerophthalmia, glaucoma and the like.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition, a preparation method thereof and application of the traditional Chinese medicine composition in preparation of medicines for treating ophthalmic diseases. The traditional Chinese medicine composition provided by the invention is prepared from the following raw materials: flos chrysanthemi, concha haliotidis, semen cassiae torae, honey-fried licorice root and a component A, wherein the component A is selected from at least one of herba schizonepetae, radix puerariae and herba menthae. The composition has the effects of removing heat from the liver and purging heat, and treating red and astringent eye pain, and experiments show that the composition can improve the tear secretion amount, prolong the tear film rupture time and / or protect the corneal epithelium. The traditional Chinese medicine composition can be clinically used for treating dry eyes, asthenopia, keratoconjunctivitis, cataract and vitreous opacity.

The invention belongs to the technical field of medicines, and particularly relates to compound tylosin ophthalmic gel as well as a preparation method and application thereof. The invention relates to compound tylosin ophthalmic gel. The compound tylosin ophthalmic gel is prepared from tylosin tartrate, ganciclovir, pharmaceutic adjuvants and water, the pharmaceutic adjuvants comprise a thickening agent, a filling agent, a solubilizer, a bacteriostatic agent and a pH regulator. The compound tylosin ophthalmic gel disclosed by the invention takes effect quickly, has a remarkable treatment effect on feline conjunctivitis, has a lasting curative effect, and can still keep a relatively good drug effect after drug withdrawal.

The present application provides a rapid detection system for allergic conjunctivitis and its application. Specifically, the present application provides a rapid detection system for detecting allergic conjunctivitis, which comprises: (A) a subject user terminal; and (B) a background processing end. The rapid detection system of the present application can timely, efficiently and accurately evaluate the incidence and severity of allergic conjunctivitis based on the detection results of the levels of IgE and histamine in tears, realize the home detection of allergic conjunctivitis, reduce misdiagnosis and avoid the aggravation of allergic conjunctivitis due to medical delay, which is helpful to improve the medical efficiency and has a broad clinical application prospect.

1. Name of the product in this design: Eye Surface Sample Sampling Bottle. 2. Purpose of this design: A tool for detecting pathogenic microorganisms in conjunctivitis secretions. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D view 1. 5. Part A is marked as being made of transparent material.

The present invention provides a composition for alleviating or preventing a symptom of allergic rhinitis or allergic conjunctivitis, the composition containing dihomo-γ-linolenic acid (DGLA) as an active ingredient.

The present invention relates to a nasal pharmaceutical composition comprising alcaftadine or a pharmaceutically acceptable salt and optionally one or more pharmaceutically acceptable excipients, methods of treating allergic rhinitis, allergic rhino-conjunctivitis, or symptoms thereof (such as nasal congestion) with the nasal pharmaceutical composition, and methods of preparing it.

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of the discomforts of dermatological disorders (e.g., diseases) The treatment is for the dysesthesia (e.g., caused by irritation, itch, or pain) due to dermatitis, urticaria; scalp itch; vulvar itch; lichen sclerosus; cholestatic itch; psoriasis; sebhorrheic dermatitis; allergic conjunctivitis; blepharitis; and pruritus of the elderly. The applicant has found that topical delivery of DIPA compounds to the skin alleviates the dysesthesia of these conditions in human subjects. The present discovery pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in the treatment of the dysesthesia of these dermatological disorders.

The invention relates to the technical field of gene engineering, in particular to a primer group for detecting a main pathogen CVA24v of acute hemorrhagic conjunctivitis based on a VP1 region and application of the primer group. The invention provides a primer group for detecting a main pathogen CVA24v of acute hemorrhagic conjunctivitis. The primer group comprises a primer pair and a probe, the nucleotide sequences of the primer pair are as shown in SEQ ID NO.1 and SEQ ID NO.3; the nucleotide sequence of the probe is as shown in SEQ ID NO. 2. The method has reliable repeatability and consistency in practical application, and is suitable for rapid and accurate identification of the main pathogen CVA24v of acute hemorrhagic conjunctivitis in clinical samples and large-scale epidemiological monitoring.

The present disclosure provides use of a polypeptide for the prevention or treatment of allergic conjunctivitis. Also provided is a method for treating or preventing allergic conjunctivitis in a subject in need thereof, comprising administering to the subject an effective amount of any one of the polypeptides disclosed herein.

The invention belongs to the technical field of biological medicine, and particularly relates to a soluble microneedle patch for in-situ drug delivery of trabecular meshwork tissue and a preparation method and application of the soluble microneedle patch. The soluble microneedle patch comprises a fan-ring-shaped backing and a microneedle array arranged on the fan-ring-shaped backing; the micro-needle and the fan-ring-shaped backing are both prepared from polyvinyl alcohol (PVA), the PVA concentration for preparing the micro-needle and the fan-ring-shaped backing is 5%-25%, and the PVA concentration is obtained by weighing 0.5 g-2. 5 g of PVA powder and dissolving the PVA powder in 10 mL of pure water or PBS. The microneedle patch is suitable for delivery of various types of drugs, is expected to be used for treatment of various eye diseases including glaucoma, ocular hypertension, cataract, uveitis, conjunctivitis, xerophthalmia and the like, and has important clinical application value and commercial value.

The application provides a feline calicivirus LZ-2016 strain and a vaccine composition. The feline calicivirus LZ-2016 strain has a high virus titer, the strain has strong pathogenicity to cats, and can cause typical symptoms such as oral ulcer and conjunctivitis. The inactivated product of the strain can produce a good immune response when cats are immunized, has good immunogenicity, can better stimulate the body to produce high-level neutralizing antibodies against FCV, can provide high immunoprotection rate to FCV attack, and has basic potential for developing a vaccine. The strain can be prepared into a vaccine and used for feline calicivirus prevention and treatment, provides an important vaccine virus source for feline calicivirus prevention and control in China, and realizes effective feline calicivirus prevention and control.

The invention relates to the technical field of medicines, and finds that a natural product amentoflavone can be used as a GPR35 (G-protein coupled receptor 35, GPR35) receptor agonist and application thereof, the compound is amentoflavone, has GPR35 receptor agonist activity, is a GPR35 receptor agonist, can be used for treating thromboembolic diseases, spring conjunctivitis, intracranial embolism, primary sclerosing cholangitis and myocardial infarction, and can be used for treating various diseases such as thromboembolic diseases, spring conjunctivitis, intracranial embolism, primary sclerosing cholangitis and myocardial infarction. Therefore, a novel GPR35 receptor stimulant seedling compound with a clear action target can be provided for the related diseases.

To provide a compound of formula (I) as described herein, pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods for using these compounds, salts, and compositions to treat viral infections. [Solution] The present invention relates to a novel 1,3-dioxoindene compound that is an inhibitor of picornaviruses, including coxsackievirus, enterovirus, echovirus, poliovirus, and rhinovirus, and is therefore useful for treating viral infections, including polio, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular diseases, hepatitis A, myositis, myocarditis, pancreatitis, diabetes mellitus, epidemic myalgia, encephalitis, common cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis, or otitis media.

Keratoconjunctivitis sicca is a general term of a plurality of diseases which are accompanied by eye discomfort and (or) ocular surface tissue lesion characteristics and are caused by tear quality or quantity abnormality or dynamic abnormality caused by any reason, and belongs to the field of chronic keratoconjunctivitis in western medicine. The common symptoms comprise eye dryness, easy fatigue, eye itching, foreign body sensation, burning pain, secretion viscosity, wind afraid, photophobia, lacrimation and external stimulation sensitivity; the two eyes of a patient with serious diseases in the later stage are red and swollen, hyperemia and keratinization, corneal epithelium exfoliation and filament adhesion exist, keratoconjunctival lesion can be caused if the patient is injured for a long time, and the continuous development of the keratoconjunctival lesion possibly causes irreversible influence on vision. The traditional Chinese medicine composition is characterized by being prepared from the following raw material medicines in parts by mass: 100 to 1000 parts of radix rehmanniae, 100 to 1000 parts of radix ophiopogonis, 100 to 1000 parts of herba dendrobii, 100 to 1000 parts of bulbus lilii, 100 to 1000 parts of radix polygonati officinalis and 200 to 500 parts of flos chrysanthemi. Corresponding auxiliary materials can also be added into the traditional Chinese medicine composition to prepare clinically common tablets, granules and oral dosage forms.

Compositions and methods for treating neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss-related, and / or metabolic diseases including Spinal Muscular Atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also known as Types I, II, III, and IV), Traumatic Brain Injury (TBI), concussion, keratoconjunctivitis sicca (dry eye disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK, antidepressant use, Wolfram syndrome, and Wolcott-Rallison syndrome. The compositions are selected from 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bis 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; bisprodrug, bioprecursor molecules, and combinations thereof.

The present invention relates to a compound of formula (I) wherein R1 and R2 are as defined herein, a pharmaceutical composition comprising such compound for treatment of a PGD2-mediated disorder including, to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like.

This invention relates to the field of product emulsification equipment technology, specifically to a nano-emulsification preparation process for a compound eye drop containing Boyunding for the treatment of canine and feline conjunctivitis. The process includes the following steps: adding the components sequentially in proportion; starting a servo motor to drive the stirring blades to rotate clockwise for shearing emulsification; simultaneously, a rotating shaft drives a rotating ring to rotate via driven teeth, causing the high-speed rotating edge liquid to impact a deflector plate and be pushed towards the center; while the rotating ring rotates, it drives the corresponding rotating plate to rotate, which in turn drives the piston plate to slide up and down within the extraction tank, continuously extracting the mixed solution; after emulsification, the discharge port is opened for dispensing and packaging. This invention, by setting up an extraction tank to continuously extract the mixed solution, ensures that the surface mixed solution is continuously squeezed into the area covered by the stirring blades, improving the mixing effect and efficiency; and by using a deflector plate to continuously push the edge mixed solution towards the center, further reducing mixing dead zones and improving the mixing effect and efficiency.

The present disclosure relates to peptide compositions and methods for treating an inflammatory condition such as ocular inflammation, retinal inflammation, dry eye, uveitis, allergic conjunctivitis, and inflammation resulting from nerve injury or nerve degeneration. The peptide compositions disclosed herein can also be used for treating pain such as neuropathic pain, ocular pain, chronic pain, pain resulting from chemotherapy or radiation, pain resulting from nerve injury or nerve degeneration, and pain resulting from an inflammatory condition, dysesthesia, or allodynia.

The invention relates to the field of medicines, in particular to fluoroalkanes, and a composition, a preparation method and application thereof. The invention has the following advantages: the invention provides fluoroalkane, and a composition, a preparation method and application thereof; the compound shown in the formula (I) or the pharmaceutically acceptable salt, the stereoisomer, the isotope variant, the solvate or the composition of the compound has the effects of stabilizing a tear film, dissolving meibolipid, dissolving earwax, inhibiting evaporation of water on the ocular surface, increasing the thickness of a tear film lipid layer, improving the spreadability of cornea, wetting the surface of the eye, preserving an isolated organ, improving the stability of the cornea and improving the quality of the eye. The pharmaceutical composition has the effects of improving the stability of a tear film, reducing the evaporation rate of tears, prolonging the rupture time of the tear film, treating meibomian fat abnormity, treating meibomian gland dysfunction, treating keratoconjunctivitis sicca, treating eye or ear related diseases such as xerophthalmia related diseases and / or delivering active pharmaceutical ingredients.

This invention belongs to the field of biomedical technology, specifically relating to a pharmaceutical composition for treating allergic conjunctivitis in children, its preparation method, and its uses. The pharmaceutical composition of this invention comprises hsa-miR-19b mimic and an immune peptide, wherein the immune peptide is a fusion peptide NGF-FGF, a combination of nerve growth factor (NGF) and fibroblast growth factor (FGF). In vitro and in vivo experiments have confirmed that hsa-miR-19b mimic and the fusion peptide NGF-FGF can alleviate the course of allergic conjunctivitis in children and reduce allergic symptoms by inhibiting the expression of inflammatory factors and reducing inflammatory responses.

The disclosure relates to an aqueous ophthalmic pharmaceutical composition including: a) at least 0.4% w / v of bilastine, of formulaor a pharmaceutically acceptable salt or solvate thereof, wherein the bilastine salt or solvate thereof is completely dissolved in the pharmaceutical composition; b) at least one β-cyclodextrin; and c) at least one pharmaceutically acceptable water-soluble gelling agent; and wherein the pH is comprised between 4 and 9. Use of the composition is described for the treatment and / or prevention of conditions mediated by H1 histamine receptor, such as allergic disorders or diseases. The treatment and / or prevention of allergic conjunctivitis is described.

The present invention relates to a sterile ophthalmic composition comprising castor oil and medium-chain triglycerides; to the use of said composition in medicine, in particular for the treatment and / or prevention of an ocular disease selected from the group consisting of dry eye, conjunctivitis, dermatitis, blepharitis, entropion, lax eye lid syndrome, thyroid eye disease, pterygium, conjunctival laxity, epithelial damage caused by preservatives, epithelial or anterior chamber damage caused by ocular surgery, corneal limbal cell deficiency, corneal ulceration caused by physical or chemical agents, keratitis, sub-scleritis and uveitis.

The application provides a double-stranded oligonucleotide targeting ALOX15 mRNA and an application thereof, and relates to the technical field of biotechnology. A sense strand nucleotide sequence of the double-stranded oligonucleotide comprises a sequence with no more than 8 nucleotides different from the sequence shown in SEQ ID NO. 1, 3, 5, 7 or the like; an antisense strand nucleotide sequence is a sequence with no more than 8 nucleotides different from the sequence shown in SEQ ID NO. 2, 4, 6, 8 or the like; and the sense strand and the antisense strand are at least partially reverse complementary to form a duplex region. The double-stranded oligonucleotide can inhibit ALOX15 mRNA and reduce ALOX15 protein expression in a subject. The double-stranded oligonucleotide can be used for preparing a medicine for treating and / or preventing ALOX15 related diseases (allergic conjunctivitis and dry eye).